Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved three new treatment combinations for ESR1-mutated, hormone receptor-positive, HER2-negative advanced breast cancer in quick succession. The latest approval — giredestrant plus everolimus — nearly doubled progression-free survival compared to standard endocrine therapy. These approvals mark a major shift in how oncologists can tackle treatment-resistant metastatic breast cancer.
The FDA has approved three new combination regimens for patients with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer in a matter of months — a wave of approvals reshaping the treatment landscape for one of the most common forms of treatment-resistant breast cancer.
The most recent approval (November 2026) covers giredestrant (Wilserdly) plus everolimus, based on the evERA Breast Cancer trial. In patients with ESR1-mutated tumors, the combo delivered a median PFS of 10 months vs. 5.5 months with physician's choice of endocrine therapy plus everolimus. Before that, the FDA approved imlunestrant (Inluriyo) plus abemaciclib (September 2026), based on the EMBER-3 trial, showing a median PFS of 11.1 months vs. 5.5 months with imlunestrant alone in ESR1-mutated patients. And in early September, camizestrant (Etcamah) plus a CDK4/6 inhibitor received accelerated approval based on SERENA-6 — notably the first FDA approval of a cancer treatment switch triggered by ctDNA testing rather than radiographic disease progression.
By the Numbers:
Why it matters: ESR1 mutations develop in roughly 30–50% of patients on aromatase inhibitor therapy and drive endocrine resistance — a major clinical hurdle. These three approvals give oncologists multiple new, biomarker-driven options to combat resistance, with companion diagnostics now approved to identify eligible patients.